10-QPeriod: Q2 FY2021

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q2 Ended Jun 30, 2021

Filed July 30, 2021For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. (VRTX) reported its second-quarter and first-half financial results for the period ending June 30, 2021. The company experienced a significant increase in product revenues, driven by strong performance of its cystic fibrosis (CF) treatments, TRIKAFTA/KAFTRIO, particularly in Europe and the U.S. However, net income saw a substantial decrease compared to the prior year, largely due to a $900 million upfront payment made to CRISPR Therapeutics in connection with an amendment to their collaboration agreement for the gene-editing therapy CTX001. Despite the hit to net income from the CRISPR payment, Vertex maintains a strong liquidity position with over $6.7 billion in cash, cash equivalents, and marketable securities. The company continues to invest heavily in research and development, with a particular focus on expanding its CF franchise and advancing its pipeline of cell and gene therapies for other serious diseases like sickle cell disease, type 1 diabetes, and Duchenne muscular dystrophy. Investors should note the significant R&D investment and the ongoing progress in pipeline development alongside the core CF business.

Financial Highlights

48 data points
Beta

Revenue

$1.79B

87.3% Gross Margin

Net Income

$67.00M

3.7% Net Margin

EPS (Diluted)

$0.26

Total Assets

$12.22B

Cash & Equivalents

$6.06B

Free Cash Flow

-$249.60M

Financial Statements
Beta
Revenue$1.79B
Cost of Revenue$228.00M
Gross Profit$1.57B
R&D Expenses$1.41B
SG&A Expenses$194.60M
Operating Expenses$1.83B
Operating Income-$37.90M
Net Income$67.00M
EPS (Basic)$0.26
EPS (Diluted)$0.26
Shares Outstanding (Basic)259.00M
Shares Outstanding (Diluted)261.00M

Key Highlights

  • 1Product revenues increased by 18% year-over-year in Q2 2021 to $1.79 billion, driven by TRIKAFTA/KAFTRIO's strong uptake.
  • 2Net income decreased by 92% in Q2 2021 to $66.9 million, primarily due to a $900 million upfront payment to CRISPR.
  • 3Cash, cash equivalents, and marketable securities stood at $6.71 billion as of June 30, 2021, indicating a strong liquidity position.
  • 4Research and development expenses surged by 234% in Q2 2021 to $1.41 billion, largely driven by the CRISPR collaboration payment.
  • 5Vertex received FDA approval for TRIKAFTA in children aged 6-11 years and Health Canada authorization for TRIKAFTA for ages 12+.
  • 6The company advanced its CTX001 gene-editing therapy program for sickle cell disease and beta thalassemia, with promising early data.
  • 7A new $1.5 billion share repurchase program was authorized in June 2021.

Frequently Asked Questions

Vertex's revenue growth is primarily driven by its cystic fibrosis (CF) franchise, particularly the triple combination therapy TRIKAFTA/KAFTRIO. The strong uptake of KAFTRIO in Europe and continued performance of TRIKAFTA in the U.S. are key contributors to the increasing product revenues.

The significant decrease in net income was primarily due to a $900 million upfront payment made to CRISPR Therapeutics in the second quarter of 2021. This payment was part of an amendment to their collaboration agreement for the development of CTX001, a gene-editing therapy. This one-time expense heavily impacted profitability for the period.

Vertex continues to invest heavily in research and development, with a diversified pipeline. Key areas of focus include expanding its CF treatments, advancing gene therapies for sickle cell disease and beta thalassemia (CTX001), and developing therapies for other serious diseases such as Type 1 diabetes, APOL1-mediated kidney diseases, and pain. The substantial increase in R&D expenses reflects these ongoing investments.

Vertex maintains a strong liquidity position, with over $6.7 billion in cash, cash equivalents, and marketable securities as of June 30, 2021. The company plans to fund its operations and future capital requirements through existing cash flows, product sales, and potentially through its revolving credit facilities or other financing options. A new $1.5 billion share repurchase program was also authorized, indicating confidence in its financial stability.